Profile data is unavailable for this security.
About the company
Appili Therapeutics Inc. is a Canada-based biopharmaceutical company. The Company is advancing a diverse range of anti-infectives, including a vaccine candidate to eliminate a serious biological weapon threat, a topical antiparasitic for the treatment of a disfiguring disease, and a novel easy to use, liquid oral formulation targeting parasitic and anaerobic infections. The Company’s anti-infective product development portfolio includes three programs, including ATI-1701, ATI-1801 and ATI-1501. ATI-1701 is a novel, live-attenuated vaccine for Francisella tularensis (F. tularensis). ATI-1801 is a novel topical formulation of paromomycin (15% w/w) under advanced clinical development for the treatment of cutaneous leishmaniasis, a disfiguring infection of the skin that affects hundreds of thousands of people around the world annually. The ATI-1501 is a taste-masked liquid oral suspension formulation of the antibiotic metronidazole.
- Revenue in CAD (TTM)1.15m
- Net income in CAD-5.34m
- Incorporated2015
- Employees8.00
- LocationAppili Therapeutics Inc#21-1344 Summer StreetHALIFAX B3H 0A8CanadaCAN
- Phone+1 (902) 442-4655
- Fax+1 (902) 442-4655
- Websitehttps://appilitherapeutics.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Eve & Co Inc | 7.77m | -5.92m | 3.74m | -- | -- | -- | -- | 0.4817 | -0.2055 | -0.2055 | 0.2698 | 0.733 | 0.1519 | 0.7493 | 8.73 | -- | -11.58 | -- | -24.24 | -- | -3.10 | -- | -76.22 | -- | 0.062 | -5.05 | 0.4892 | -- | 2.94 | -- | -71.97 | -- | -- | -- |
Appili Therapeutics Inc | 1.15m | -5.34m | 4.25m | 8.00 | -- | -- | -- | 3.70 | -0.044 | -0.044 | 0.0095 | -0.0811 | 0.5047 | -- | 2.12 | -- | -234.31 | -117.41 | -- | -173.66 | -- | -- | -464.23 | -3,037.15 | -- | -5.32 | -- | -- | -75.97 | -- | 63.20 | -- | -43.04 | -- |
Entourage Health Corp | 40.71m | -46.17m | 4.61m | 251.00 | -- | -- | -- | 0.1132 | -0.150 | -0.150 | 0.1324 | -0.4776 | 1.05 | 2.84 | 12.12 | -- | -118.59 | -55.14 | -- | -150.92 | 13.37 | -40.59 | -113.40 | -199.99 | 0.0893 | -0.8073 | 11.31 | -- | -0.438 | 38.62 | 62.51 | -- | -49.49 | -- |
Innovotech Inc | 1.18m | -157.59k | 4.69m | 16.00 | -- | 5.03 | -- | 3.96 | -0.004 | -0.004 | 0.0304 | 0.0239 | 0.9696 | 6.62 | 5.51 | -- | -12.92 | 2.90 | -15.52 | 3.56 | 68.63 | 71.56 | -13.33 | 2.19 | 2.82 | -- | 0.00 | -- | 5.05 | 7.42 | -15.43 | -- | 35.69 | -- |
StageZero Life Sciences Ltd | 4.08m | -17.07m | 4.92m | 40.00 | -- | -- | -- | 1.21 | -0.1609 | -0.1609 | 0.0377 | -0.10 | 0.6717 | 22.87 | 48.05 | 101,923.90 | -281.22 | -135.76 | -- | -- | 0.3457 | -2.74 | -418.64 | -246.92 | 0.0329 | -14.74 | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
Principal Technologies Inc | 581.16k | -1.52m | 4.94m | -- | -- | 6.07 | -- | 8.49 | -0.0657 | -0.0657 | 0.0257 | 0.0247 | 0.577 | -- | 3.71 | -- | -147.50 | -- | -286.94 | -- | 42.98 | -- | -255.65 | -- | -- | -59.80 | 0.0757 | -- | 25.43 | -- | 23.53 | -- | -- | -- |